ACQUISITION OF MEDICINES OUTSIDE THE NATIONAL BASIC MEDICINE LIST: RAVULIZUMAB PARENTERAL LIQUID 100 MG/ML FOR PATIENT RA.ME.AN.DA. CONFIDENTIALITY CODE WITH DIAGNOSIS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

This tender concerns the acquisition of a specific pharmaceutical product, Ravulizumab, a parenteral liquid formulation of 100 mg/ml, intended for a patient identified by the confidentiality code RA.ME.AN.DA. The patient has been diagnosed with Paroxysmal Nocturnal Hemoglobinuria (PNH). This medication is classified as being outside the National Basic Medicine List, indicating its specialized nature and potential high cost. The contracting entity is HOSPITAL DEL NIÑO FY. The procurement process is identified by code RE-PU-HFIB-2025-005-29399. The contract modality is specified as "Bienes y Servicios únicos" (Unique Goods and Services), suggesting a sole-source or highly specialized procurement. The required quantity for Ravulizumab is 58 units, with an estimated unit cost of USD 3,181.26. Eligibility criteria are defined under "Otros Parámetros de Calificación" (Other Qualification Parameters), implying that bidders will be assessed based on specific, potentially non-standard, qualifications beyond basic requirements. This procurement is critical for ensuring the continuity of treatment for a patient with a rare and serious hematological condition, requiring access to advanced and specialized pharmaceutical interventions.

This is a supplies contract in the governance and public administration sector. Located in Ecuador, Latin America, this opportunity is open to firms and consortiums, with an estimated budget of USD 184,513.

Published through SERCOP Ecuador, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the governance and public administration sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.